Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

The trial did not meet its primary endpoint, however, the totality of data supports Barostim’s use as an effective treatment for patients with heart failure

News | Heart Failure

CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial

February 22, 2023 — CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and ...

February 22, 2023

First U.S. study to show lower risk in patients following SARS-CoV-2 infection

News | Coronavirus (COVID-19)

COVID-19 Vaccination Linked to Fewer Cardiac Events

February 21, 2023 — Analyzing the most extensive datasets in the United States, researchers from the Icahn School of ...

February 21, 2023

A research analysis of individuals who had experienced strokes showed greater cerebral blood flow regulation during afternoon hours compared to morning and night times

News | Stroke

Daily Rhythm Detected for Cerebral Blood Flow in Stroke Patients

February 21, 2023 — Strokes are a leading cause of morbidity and mortality in the United States, as well as around the ...

February 21, 2023

NEXLETOL (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint –

News | Cardiovascular Clinical Studies

Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC

February 20, 2023 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting ...

February 20, 2023

A novel preclinical model of ischemic stroke suggests uric acid improves functional outcomes

News | Stroke

SPAN Results, Monitoring Ischemic Stroke in Small- and Large-vessel Disease and Positive Neuroprotective Effects from Aptamer

February 20, 2023 — A novel Stroke Preclinical Assessment Network (SPAN) identified potential neuroprotective effects ...

February 20, 2023

Medtronic plc has received CE (Conformité Européenne) Mark for the Aurora EV-ICD MRI SureScan (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV MRI SureScan defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest.

News | Implantable Cardioverter Defibrillator (ICD)

Medtronic Receives CE Mark for Extravascular Defibrillator System That Treats Abnormal Heart Rhythms

February 17, 2023 — Medtronic plc has received CE (Conformité Européenne) Mark for the Aurora EV-ICD MRI SureScan ...

February 17, 2023

The American College of Cardiology (ACC) has announced five Late-Breaking Clinical Trial Sessions, two Late-Breaking Clinical Trial Deep Dive Sessions, and three Featured Clinical Research sessions to be presented during its annual scientific session, “ACC with WCC,” or ACC.23/WCC to be held March 4-6 in New Orleans, LA.

Feature | ACC | Christine Book

Late-breaking Clinical Trials, Featured Clinical Research Sessions Announced for American College of Cardiology ACC.23/WCC

February 16, 2023 — The American College of Cardiology (ACC) has announced five Late-Breaking Clinical Trial Sessions ...

February 16, 2023

Noise-induced stress causes the release of stress hormones that trigger an inflammatory response, leading to more severe myocardial infarction, oxidative stress and endothelial dysfunction, and subsequent heart failure.

News | Cardiovascular Clinical Studies

Aircraft Noise Increases Damage from Myocardial Infarction

February 16, 2023 — Traffic noise may play an essential role in the development and deterioration of ischemic heart ...

February 16, 2023

LACI-2 shows reduction in cognitive decline after lacunar stroke

News | Stroke

ISC23 Late-breaker: A New Strategy to Improve Stroke Thrombolysis

February 15, 2023 — Thrombolysis use increased from 4% in 2010 to 14% in 2020 in the traditionally underserved urban ...

February 15, 2023

VST-Bio's Collaborators Present Preclinical Trial Results at the American Heart Association International Stroke Conference in Dallas.

News | Stroke

VST-BIO Announces Successful Preclinical Trials in Ischemic Stroke

February 14, 2023 — VST-Bio Corp. a leader in the development of innovative biologics to treat acute and chronic cardiov ...

February 14, 2023

Late breaking analysis of one-year outcomes from the inspIRE clinical study demonstrated early success at the prespecified interim analysis

News | Atrial Fibrillation

First Look at Data on Biosense Webster's Investigational Pulsed Field Ablation Platform Presented at AF Symposium 2023

February 14, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

February 14, 2023

Led by University Hospitals stroke director Amrou Sarraj, MD, SELECT2 study results in New England Journal of Medicine presented at International Stroke Conference

News | Stroke

New Major International Study Finds Thrombectomy Highly Effective Treatment for Large Strokes

February 14, 2023 — A large international clinical study finds that patients with large strokes had a dramatically ...

February 14, 2023

Lowering blood pressure after clot removal may not be safe, and should be individualized, according to findings of the BEST II Trial presented during the American Stroke Association International Stroke Conference. Photo credit: Getty Images

News | Stroke

BEST II Clinical Trial Findings Reported at International Stroke Conference: Proceed with Caution on Blood Pressure Meds after Clot Removal

February 14, 2023 — Using blood pressure medications to lower systolic blood pressure immediately after mechanical clot ...

February 14, 2023

The late-breaking results from STROKE AF study reinforce importance of long-term continuous cardiac monitoring in ischemic stroke patients

News | Stroke

Late-breaking Results from STROKE AF Study at ISC23

February 8, 2023 —Medtronic announced late-breaking clinical data from the STROKE AF clinical study, which showed large ...

February 08, 2023

Life Molecular Imaging (LMI) announced that the first patient has been imaged with [18F]florbetaben in the CArdiag Phase 3 clinical study

News | Cardiovascular Clinical Studies

Life Molecular Imaging Announces Start of Phase 3 Study with [18F]Florbetaben in Cardiac Amyloid Light Chain (AL) Amyloidosis

February 8, 2023 — Life Molecular Imaging (LMI) announced that the first patient has been imaged with [18F]florbetaben i ...

February 08, 2023